Understanding the complex regulatory mechanisms of AMPK-regulated pathways may increase the opportunity to develop better effective drugs to prevent NAFLD, thereafter decreasing the incidence of further liver diseases such as NASH, fibrosis, and cancer. Here, PRKAB1 is linked to metabolic dysfunction-associated steatotic liver disease.